Sientra Announces miraDry Leadership Transition


SANTA BARBARA, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN), a medical aesthetics company, announced today that it has appointed Kirk Gunhus to the position of General Manager of miraDry, effective immediately. Mr. Gunhus succeeds Patrick Williams, who is leaving Sientra. Keith Sullivan, a member of Sientra’s Board of Directors who has been integral to the success of miraDry to date, will continue in his role as Strategic Advisor to the miraDry business. 

Mr. Gunhus is a seasoned executive with over 20 years of experience in scaling global commercial organizations in the aesthetics and medical devices industry. He joined Sientra in January 2018 as Vice President and head of international sales at miraDry. Under Mr. Gunhus’ strong leadership, miraDry has gained significant traction internationally, achieving four successive quarters of sales over-performance. Mr. Gunhus joined Sientra from Zeltiq, where he spent over seven years as a senior commercial executive driving rapid aesthetic practice adoption of new technologies and developing and accelerating growth in new markets. Prior to that, Mr. Gunhus held senior positions at Medicis Pharmaceutical and CIBA Vision.

Jeffrey M. Nugent, Chairman and Chief Executive Officer of Sientra, said, “Kirk is a proven commercial and operational leader, with an established track record of building high performing sales and marketing organizations, increasing salesforce productivity, and driving market penetration.  miraDry’s innovative technology has tremendous runway for growth in the United States and I am excited for Kirk to pursue the successful growth strategies he developed while leading miraDry’s international commercial organization. I am confident that under Kirk’s leadership, we are well positioned to achieve the goals we have established for this unique market opportunity.”

Mr. Nugent concluded, “I would like to thank Patrick for his dedicated service to Sientra and for the many contributions he has made to our growth and success. We wish him the best and continued success in his future endeavors.”

About Sientra
Headquartered in Santa Barbara, California, Sientra is a diversified global medical aesthetics company and a leading partner to aesthetic physicians. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes.   The Company’s Breast Products Segment includes its OPUS™ breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology,  and BIOCORNEUM® the #1 performing, preferred and recommended scar gel of plastic surgeons(*).  The Company’s miraDry Segment, comprises its miraDry® system, which is approved for sale in over 40 international markets, and is the only non-invasive FDA-cleared device for the permanent reduction of underarm sweat, odor and hair of all colors.
(*) Data on file

Investor Contacts:
Neil Bhalodkar



Source: Sientra, Inc.

Nasdaq: SIEN

Stock Quote: NASD

$0.84 -0.04
Volume 452,889
Previous Close 0.88
Intraday High 0.89
Intraday Low 0.81
Pricing delayed 20 minutes
Price Change % Change -4.95% 52 Week High 9.14 52 Week Low 0.80 Today's Open 0.89 Jun 29, 2022 04:00 PM

Investor Contact

Sientra Investor Relations